Login
iSpecimen Inc. logo

iSpecimen Inc.

ispecimen.com

What Do They Do?

Connects life-science researchers at biopharmaceutical, diagnostic, and government or academic organizations with human biospecimens and associated data through an online marketplace.

How Do They Make Money?

Researchers pay iSpecimen for specimens sourced from hospitals, laboratories, and other supply sites; iSpecimen distributes part of the revenue to the supplying organizations.

revenue
SegmentShareRevenue
Specimens - contracts with customers
Sold outright

90%
FY2022: 96%
Shipping and other
10%
FY2022: 4.3%

Who Are Their Customers?

Biopharmaceutical companies, in vitro diagnostic companies, and government and academic institutions use the online marketplace to search for and order specimens; healthcare providers supply them.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2024: 22% from one customer

Do Revenues Turn Into Profits?

No. It lost $10.5M in FY2025.

Operating income, FY2025
−465% of revenue
▲ +29% (Loss) vs FY2024 (−$12.7M, −137%)
Net income, FY2025
−544% of revenue
▲ +16% (Loss) vs FY2024 (−$12.5M, −135%)
Free cash flow, FY2025
−220% of revenue
▲ +49% (Loss) vs FY2024 (−$8.3M, −89%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Revenue
▼ −79%
vs $713.1K in Q2 FY2025
Net income
▼ −30% (Loss)
vs −$1M in Q2 FY2025
Specimens - contracts with customers share of revenue vs 94.2% in Q2 FY2025
  • Nov 2, 2026 Acquired AI products for protein discovery and disease trend monitoring The assets include an AI agent for protein discovery and a model for predicting and monitoring disease trends.
  • Sep 8, 2026 Nasdaq extended the deadline to meet a continued-listing equity requirement The company must provide evidence of compliance by the extended deadline or may face delisting.
  • Aug 26, 2026 Shahin Behroyan became CEO as Katharyn Field transitioned to an advisory role

New sequencing initiative The latest report adds a Next Generation Sequencing initiative to the adjacent opportunities it is pursuing, alongside clinical-trial recruitment, data products, and software subscriptions.

Revenue over time
Specimens - contracts with customers Shipping and other
$20M$10M$0

Who Do They Compete With?

Competes with Discovery Life Sciences, StemExpress, and Science Exchange

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support